Stabilization of luteinizing hormone-releasing hormone in a dry powder formulation and its bioactivity

1. Tsai PS. Gonadotropin-releasing hormone in invertebrates: structure, function and evolution. Gen Comp Endocrinol. 2006; 148: 48-53.10.1016/j.ygcen.2005.09.016Search in Google Scholar

2. Fernald RD, White RB. Gonadotropin-releasing hormone genes: phylogeny, structure and function. Front Neuroendocrinol. 1999; 20:224-40.10.1006/frne.1999.0181Open DOISearch in Google Scholar

3. Millar RP. GnRHs and GnRH receptors. Anim Reprod Sci. 2005; 88:5-28.10.1016/j.anireprosci.2005.05.032Open DOISearch in Google Scholar

4. Belsham DD, Lovejoy DA. Gonadotropin-releasing hormone: gene evolution, expression and regulation. Vitam Horm. 2006; 71:59-94.10.1016/S0083-6729(05)71003-7Open DOISearch in Google Scholar

5. Powell MF, Sanders LM, Rogerson A, Si V. Parenteral peptide formulations: Chemical and physical properties of native luteinizing hormone-releasing hormone (LHRH) and hydrophobic analogues in aqueous solution. Pharm Res. 1991; 10:1258-63.10.1023/A:1015847628047Open DOISearch in Google Scholar

6. Mezo G, Manea M. Luteinizing hormone-releasing hormone antagonists. Expert OpinTher Pat. 2009; 19: 1771-85.10.1517/1354377090341023719939192Search in Google Scholar

7. Akaza H. Future prospects for luteinizing hormonereleasing hormone analogues in prostate cancer treatment. Pharmacology. 2010; 85:110-20.10.1159/00027448620130444Search in Google Scholar

8. Vercellini P, Somigliana E, Vigan_ P, Abbiati A, Barbara G, Crosignani PG. Endometriosis: current therapies and new pharmacological developments. Drugs. 2009; 69: 649-75.10.2165/00003495-200969060-0000219405548Open DOISearch in Google Scholar

9. Hackshaw A. Luteinizing hormone-releasing hormone (LHRH) agonists in the treatment of breast cancer. Expert Opin Pharmacother. 2009; 10:2633-9.10.1517/1465656090322498019874248Search in Google Scholar

10. Helm VJ, Muller BW. Stability of gonadorelin and triptorelin in aqueous solution. Pharm Res. 1990; 12: 1253-6.10.1023/A:1015981704133Open DOISearch in Google Scholar

11. Pikal M. Freeze-drying of proteins, Part II. Formulation selection. Biopharmaceutics. 1990; 3:26-30.Search in Google Scholar

12. Prestrelski S, Tedeschi N, Arakawa T, Carpenter JDehydration induced conformation transitions in proteins and their inhibition by stabilizers. Biophys J. 1993; 65: 661-71.10.1016/S0006-3495(93)81120-2Open DOISearch in Google Scholar

13. Allison SD, Chang B, Randolph TW, Carpenter J. Hydrogen bonding between sugar and protein is responsible for inhibition of dehydration-induced protein unfolding. Arch Biochem Biophys. 1999; 365: 289-98.10.1006/abbi.1999.1175Search in Google Scholar

14. Eriksson HJ, Hinrichs WL, van Veen B, Somsen GW, de Jong GJ, Frijlink HW. Investigations into the stabilization of drugs by sugar glasses: I. Tablets prepared from stabilized alkaline phosphatase. Int J Pharm. 2002; 249:59-70.10.1016/S0378-5173(02)00531-8Search in Google Scholar

15. Arakawa T, Timasheff SN. Stabilization of protein structure by sugars. Biochemistry. 1982; 21:6536-44.10.1021/bi00268a033Open DOISearch in Google Scholar

16. Arakawa T, Timasheff SN. Preferential interactions of proteins with salts in concentrated solutions. Biochemistry. 1983; 21:6545-52.10.1021/bi00268a034Open DOISearch in Google Scholar

17. Arakawa T, Timasheff SN. Mechanism of protein salting in and salting out by divalent cations: balance between hydration and salt binding. Biochemistry. 1984; 23: 5912-23.10.1021/bi00320a004Open DOISearch in Google Scholar

18. Carpenter JP, Hand SC, Crowe LM, Crowe JH. Cryoprotection of phosphofructokinase with organic solutes: characterization of enhanced protection in the presence of divalent cations. Arch Biochem Biophys. 1986; 250:505-12.10.1016/0003-9861(86)90755-1Search in Google Scholar

19. Carpenter JF, Crowe JH. The mechanism of cryoprotection of proteins by solutes. Cryobiology. 1988; 25:244-55.10.1016/0011-2240(88)90032-6Open DOISearch in Google Scholar

20. Crowe JH, Crowe LM, Carpenter JF, Aurell Wistrom C. Stabilization of dry phospholipids bilayers and proteins by sugars. Biochem J. 1987; 242:1-10.10.1042/bj2420001Search in Google Scholar

21. Wang W. Instability stabilization and formulation of liquid protein pharmaceutical. Int J Pharm. 1999; 185: 129-88.10.1016/S0378-5173(99)00152-0Search in Google Scholar

22. Wang W. Lyophilization and development of solid protein pharmaceutical. Int J Pharm. 2000; 203:1-6010.1016/S0378-5173(00)00423-3Search in Google Scholar

23. Liao YH, Brown MB, Martin GP. Investigation of the stabilization of freeze-dried lysozyme and the physical properties of the formulations. Eur J Pharm Biopharm. 2004; 58:15-24.10.1016/j.ejpb.2004.03.020Open DOISearch in Google Scholar

24. Nata a J, Andanne B, Marc S, Michiel VS, Gerard WH, Geert JW, Daan JA, Wim J. Stable sugar-based protein formulations by supercritical fluid drying. Int J Pharm. 2008; 346:102-8.10.1016/j.ijpharm.2007.06.013Search in Google Scholar

25. Wearley LL. Recent progress in protein and peptide delivery by non-invasive routes. Crit Rev Ther Drug Carrier Syst. 1991; 8:1331-94.Search in Google Scholar

26. Adjei AL, Gupta PK. Inhalation delivery of therapeutic peptides and proteins. New York:Marcel Dekker, 1997. p. 15-20.Search in Google Scholar

27. Srichana T, Suedee R, Srisudjai P. Application of spectrofluorometry for evaluation of dry powder inhalers in vitro. Pharmazie. 2003; 58:125-129.Search in Google Scholar

28. Johnson KA. Preparation of peptide and protein powders for inhalation. Adv Drug Deliv Rev. 1997; 26: 3-15.10.1016/S0169-409X(97)00506-1Open DOISearch in Google Scholar

29. Schule H, Mechanisms and factors affecting intrapulmonary particle deposition: implications for efficient inhalation therapies. Pharm Sci Technol Today. 1998; 1:326-34.10.1016/S1461-5347(98)00089-3Search in Google Scholar

30. Gerrit SZ, Wouter LJH, Anne HB, Henderik WF. The role of particle engineering in relation to formulation and de-agglomeration principle in the development of a dry powder formulation for inhalation of cetrorelix. Eur J Pharm Sci. 2004; 23:139-49.10.1016/j.ejps.2004.06.00515451002Open DOISearch in Google Scholar

31. Crowder TM, Rosati JA, Schroeter JD, Hickey AJ, Martonen TB. Fundamental effect of particle morphology on lung delivery: predictions of Stokes’ law and the particular relevance to dry powder inhaler formulation and development. Pharm Res. 2002; 19: 239-45.10.1023/A:1014426530935Open DOISearch in Google Scholar

32. Gharib SD, Wierman ME, Badger TM, Chin WW. Sex steroid hormone regulation of follicle-stimulating hormone subunit messenger ribonucleic acid (mRNA)levels in the rat. J Clin Invest. 1987; 80:294-9.10.1172/JCI1130724422373112183Open DOISearch in Google Scholar

33. Nelson LM, Cox MM. Lehninger principle of biochemistry. New York; 2002. p. 118-9.Search in Google Scholar